Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763775 | 1.00 | LMNA (0.34) | LMNATSHRKMT2AMEN1NPC1 | |
| SCHEMBL30915236 | 1.00 | LMNA (0.34) | LMNATSHRKMT2AMEN1NPC1 | |
| SCHEMBL1457093 | 1.00 | LMNA (0.34) | LMNATSHRKMT2AMEN1NPC1 | |
| SCHEMBL30915237 | 1.00 | LMNA (0.34) | LMNATSHRKMT2AMEN1NPC1 | |
| SCHEMBL8505944 | 0.86 | DRD4 (0.34) | NPC1CTNNB1 | |
| SCHEMBL8542898 | 0.86 | DRD4 (0.34) | NPC1CTNNB1 | |
| SCHEMBL16378821 | 0.85 | KMT2A (0.35) | LMNATSHRKMT2AMEN1NPC1 | |
| SCHEMBL7683910 | 0.83 | ALDH1A1 (0.32) | CTNNB1 | |
| SCHEMBL6763805 | 0.83 | MGLL (0.33) | TSHRKMT2AMEN1NPC1HRH4 | |
| SCHEMBL6763809 | 0.83 | MGLL (0.33) | TSHRKMT2AMEN1NPC1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886774-A | Preparation method of fluoxastrobin intermediate | 江苏好收成韦恩农化股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| EP-3303312-B1 | PROCESS FOR PREPARING (E)-(5,6-DIHYDRO-1,4,2-DIOXAZINE-3-YL)(2-HYDROXYPHENYL)METHANONE O-METHYL OXIME | ARYSTA LIFESCIENCE CORP (JP) | 2023-07-19 | — | — | EP | claimed |
| EP-3699178-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | Arysta LifeScience Corporation (JP) | 2020-08-26 | — | — | EP | claimed |
| EP-3019495-B1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORP (JP) | 2020-06-03 | — | — | EP | claimed |
| US-10087152-B2 | Process for preparing (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime | ARYSTA LIFESCIENCE CORPORATION (JP) | 2018-10-02 | — | — | US | claimed |
| US-20180148423-A1 | Process for Preparing (E)-(5,6-Dihydro-1,4,2-Dioxazine-3-YL) (2-Hydroxyphenyl) Methanone O-Methyl Oxime | ARYSTA LIFESCIENCE CORPORATION (JP) | 2018-05-31 | — | — | US | claimed |
| EP-3303312-A1 | PROCESS FOR PREPARING (E)-(5,6-DIHYDRO-1,4,2-DIOXAZINE-3-YL) (2-HYDROXYPHENYL) METHANONE O-METHYL OXIME | Arysta LifeScience Corporation (JP) | 2018-04-11 | — | — | EP | claimed |
| US-9670171-B2 | Process for preparing fluoxastrobin | ARYSTA LIFESCIENCE CORP (JP) | 2017-06-06 | — | — | US | claimed |
| WO-2016193822-A1 | PROCESS FOR PREPARING (E)-(5,6-DIHYDRO-1,4,2-DIOXAZINE-3-YL) (2-HYDROXYPHENYL) METHANONE O-METHYL OXIME | ARYSTA LIFESCIENCE CORPORATION (JP) | 2016-12-08 | — | — | WO | claimed |
| US-20160237047-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORP (JP) | 2016-08-18 | — | — | US | claimed |
| EP-3019495-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | Arysta LifeScience Corporation (JP) | 2016-05-18 | — | — | EP | claimed |
| US-9193698-B2 | Process for preparing fluoxastrobin | ADVINUS THERAPEUTICS, LTD. (IN) | 2015-11-24 | — | — | US | claimed |
| WO-2015006203-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORPORATION (JP) | 2015-01-15 | — | — | WO | claimed |
| US-20150011753-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | ARYSTA LIFESCIENCE CORPORATION (JP) | 2015-01-08 | — | — | US | claimed |
| US-12559483-B2 | Process for the preparation of fluoxastrobin and intermediates thereof | UPL LTD (IN) | 2026-02-24 | — | — | US | disclosed |
| US-12024492-B2 | Process for preparation of azoxystrobin and intermediates thereof | UPL LTD (IN) | 2024-07-02 | — | — | US | disclosed |
| CN-117886774-A | Preparation method of fluoxastrobin intermediate | 江苏好收成韦恩农化股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-6005104-A | INTERMEDIATES FOR PREPARING COMPOUNDS HAVING FUNGICIDAL PROPERTIES; PREPARED BY REARRANGING O-HYDROXYETHYL-O'-ALKYL-BENZOFURANDIONE DIOXIMES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-12-21 | — | — | US | disclosed |
| CN-1220665-A | Process for preparing 3- (1-hydroxyphenyl-1-alkoxyiminomethyl) dioxazines | BAYER AG (DE) | 1999-06-23 | — | — | CN | disclosed |
| EP-0712396-B1 | SUBSTITUTED AZADIOXACYCLOALKENES AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087152-B2 | Process for preparing (E)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)methanone O-methyl oxime | HMOX2, HAO2, HMOX1 | LMNA 1510/4885TSHR 3439/4885KMT2A 490/4885 |
| US-20160237047-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | CYP4X1, MB, HAO2 | LMNA 953/4885TSHR 2745/4885KMT2A 2793/4885 |
| US-20180148423-A1 | Process for Preparing (E)-(5,6-Dihydro-1,4,2-Dioxazine-3-YL) (2-Hydroxyphenyl) Methanone O-Methyl Oxime | HMOX2, HAO2, HMOX1 | LMNA 1627/4885TSHR 3409/4885KMT2A 470/4885 |
| US-12024492-B2 | Process for preparation of azoxystrobin and intermediates thereof | NISCH, STS, SNX2 | LMNA 2252/4885TSHR 4550/4885KMT2A 3991/4885 |
| US-12559483-B2 | Process for the preparation of fluoxastrobin and intermediates thereof | P2RX7, P2RX6, CTRB1 | LMNA 1078/4885TSHR 950/4885KMT2A 4777/4885 |
| US-20150011753-A1 | PROCESS FOR PREPARING FLUOXASTROBIN | CYP4X1, MB, HAO2 | LMNA 953/4885TSHR 2745/4885KMT2A 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.